{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:34:59Z","timestamp":1793061299696,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jchf.2025.02.021","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T14:51:29Z","timestamp":1746715889000},"page":"102452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure"],"prefix":"10.1016","volume":"13","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jchf.2025.02.021_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/ajh\/hpae003","article-title":"Moving forward by looking backwards: the role of combination therapy with a mineralocorticoid receptor antagonist and a thiazide diuretic in patients with hypertension","volume":"37","author":"Pitt","year":"2024","journal-title":"Am J Hypertens"},{"issue":"13","key":"10.1016\/j.jchf.2025.02.021_bib2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCULATIONAHA.123.064318","article-title":"Early implementation of aldosterone-targeted therapy in patients with hypertension","volume":"147","author":"Pitt","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2025.02.021_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.jchf.2025.02.021_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jchf.2025.02.021_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jchf.2025.02.021_bib6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1210\/clinem\/dgae663","article-title":"Progressive 11-beta-hydroxysteroid dehydrogenase type 2 insufficiency as kidney function declines","volume":"110","author":"Uslar","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jchf.2025.02.021_bib7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.jchf.2025.02.021_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","article-title":"Proteomic and mechanistic analysis of spironolactone in patients at risk for HF","volume":"9","author":"Ferreira","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.02.021_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-physiol-042022-015223","article-title":"The mineralocorticoid receptor in the vasculature: friend or foe?","volume":"86","author":"Ibarrola","year":"2024","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.117.10391","article-title":"Aging and adrenal aldosterone production","volume":"71","author":"Nanba","year":"2018","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.jchf.2025.02.021_bib11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCULATIONAHA.117.028201","article-title":"Age-related autonomous aldosteronism","volume":"136","author":"Nanba","year":"2017","journal-title":"Circulation"},{"issue":"38","key":"10.1016\/j.jchf.2025.02.021_bib12","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jchf.2025.02.021_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nrneph.2012.282","article-title":"Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease","volume":"9","author":"Nagase","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/ijms19020546","article-title":"The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor","volume":"19","author":"Baudrand","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jchf.2025.02.021_bib16","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an International Human Physiology Study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.jchf.2025.02.021_bib17","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","article-title":"The evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.jchf.2025.02.021_bib18","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMimc2401927","article-title":"Targeting a hormonal cause of hypertension","volume":"392","author":"Vaidya","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.124.24153","article-title":"Characterizing the origins of primary aldosteronism","volume":"82","author":"Brown","year":"2025","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jchf.2025.02.021_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jchf.2025.02.021_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the Multi-Ethnic Study of Atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2025.02.021_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155593","article-title":"Renin-independent aldosteronism and chronic kidney disease in diabetes: observational and Mendelian randomization analyses","volume":"145","author":"Hu","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.jchf.2025.02.021_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.124.070039","article-title":"Relationship between renin, aldosterone, aldosterone-to-renin ratio and arterial stiffness and left ventricular mass index in young adults","author":"Ananda","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2025.02.021_bib25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archinte.1972.03650060041007","article-title":"The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone","volume":"130","author":"Carey","year":"1972","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.jchf.2025.02.021_bib26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.jchf.2025.02.021_bib27","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1161\/HYPERTENSIONAHA.124.22884","article-title":"Comparing ARR versus suppressed PRA as screening tests for primary aldosteronism","volume":"81","author":"Marcelli","year":"2024","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jchf.2025.02.021_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/ajh.2011.263","article-title":"11Beta-hydroxysteroid dehydrogenase type 2 polymorphisms and activity in a Chilean essential hypertensive and normotensive cohort","volume":"25","author":"Campino","year":"2012","journal-title":"Am J Hypertens"},{"issue":"8","key":"10.1016\/j.jchf.2025.02.021_bib29","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/ajh\/hpy051","article-title":"Serum cortisol and cortisone as potential biomarkers of partial 11beta-hydroxysteroid dehydrogenase type 2 deficiency","volume":"31","author":"Carvajal","year":"2018","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1530\/eje.1.01954","article-title":"Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function","volume":"153","author":"Quinkler","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1210\/jc.2018-01197","article-title":"Clinical, biochemical, and genetic characteristics of \"nonclassic\" apparent mineralocorticoid excess syndrome","volume":"104","author":"Tapia-Castillo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.jchf.2025.02.021_bib32","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jchf.2025.02.021_bib33","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jchf.2025.02.021_bib34","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"47","key":"10.1016\/j.jchf.2025.02.021_bib35","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2413737121","article-title":"The glucocorticoid receptor potentiates aldosterone-induced transcription by the mineralocorticoid receptor","volume":"121","author":"Johnson","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"577","key":"10.1016\/j.jchf.2025.02.021_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau9685","article-title":"Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice","volume":"12","author":"Oakley","year":"2019","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.jchf.2025.02.021_bib37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jchf.2025.02.021_bib38","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN Randomized Clinical Trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"38","key":"10.1016\/j.jchf.2025.02.021_bib39","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jchf.2025.02.021_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jchf.2025.02.021_bib41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","article-title":"Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.jchf.2025.02.021_bib42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension: a cohort study","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.jchf.2025.02.021_bib43","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","article-title":"Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial","volume":"151","author":"Hu","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.021_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.112.194787","article-title":"Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients","volume":"60","author":"Raheja","year":"2012","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.jchf.2025.02.021_bib47","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jchf.2025.02.021_bib48","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jchf.2025.02.021_bib49","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","author":"Tuttle","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jchf.2025.02.021_bib50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.34067\/KID.0006782020","article-title":"Patiromer and spironolactone in resistant hypertension and advanced CKD: analysis of the randomized AMBER Trial","volume":"2","author":"Agarwal","year":"2021","journal-title":"Kidney360"},{"issue":"10","key":"10.1016\/j.jchf.2025.02.021_bib51","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925002549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925002549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:21:48Z","timestamp":1793060508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925002549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2213177925002549"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.02.021","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}],"article-number":"102452"}}